Agenus

AGENNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$311.476 M

$6.96 -7.08%

Close of 7 Aug 2026

Revenue

$114.2M

#2473 by revenue

Earnings

-$3.08M

Loss-making

Shares outstanding

45,020,407

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#84Fate TherapeuticsFATE$326.4M
#85Inhibikase TherapeuticsIKT$326.1M
#86AgenusAGEN$311.5M
#87Anavex Life SciencesAVXL$309.5M
#88Neumora TherapeuticsNMRA$302.0M

Where these numbers come from

Share counts and financials for Agenus are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.